PHARMACY AND THERAPEUTICS COMMITTEE
MEDICARE MEETING MINUTES
PPO-POS, HMO-POS, HMO-SNP
October 29, 2026

Attendance: *Microsoft Teams Meeting*
Dr. Paul Aitken, Medical Director; Vanessa Amilcar, Pharmacy Student Intern; Rojin Baniasadi, Pharmacy Resident; Kelly Bartolone, Staff/Clinical Pharmacist; Niki Bautista, Pharmacy Student Intern; Juby Benny, Pharmacy Student Intern; Gary Bledsoe, Staff/Clinical Pharmacist; Connie Chan, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Lauren Culbert, Pharmacy Student Intern; Danielle Dolores, Director Pharmacy Services; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Lauren Grantz, Administrator Outpatient Pharmacy Services, Jefferson Enterprise; Dr. Merleen Harris-Williams, Medical Director; Yelena Hedrick, Staff/Clinical Pharmacist; Gia Ho, Pharmacy Resident; Samantha Jackson, Formulary Pharmacist; Ruth John, Staff/Clinical Pharmacist; Sheenu Joseph, Staff/Clinical Pharmacist; Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Hannah McCaffrey, Manager Pharmacy Regulations & Implementations; Derek McFerran, Vice President, Pharmacy Operations; Michele McKenna, Staff/Clinical Pharmacist; Lisa Murray, Staff/Clinical Pharmacist; Claudia Pinketti, Staff/Clinical Pharmacist; Ryan Prager, Staff/Clinical Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Staff/Clinical Pharmacist; Tara Swartz, Staff/Clinical Pharmacist; Michelle Tran, Pharmacy Resident; Dr. Frank Urbano, Medical Director; Fallan Vaisberg, Formulary Pharmacist; Reena Varghese, Staff/Clinical Pharmacist; Jeanine Zubrzycki, Staff/Clinical Pharmacist

Excused: *Dr. Neal Demp, Community Behavior Health; Kristen DeSorte, Staff/Clinical Pharmacist; Dr. Demian Elder, Medical Director; Hailey Fry, Centennial Pharmacy; Jessica Hoang-Le, Staff/Clinical Pharmacist; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Brandi Mahler, Supervisor Pharmacy Technicians; Kateryna Puia, Clinical Programs Pharmacist; Sanjiv Raj, Associate VP Customer Engagement; Sara Sadiq, Staff/Clinical Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health*

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING	DUE DATE
Minutes Review/Approval	*D. Dolores presented the minutes from the August 2026 meeting to the Committee for review.*	*The Committee approved the minutes from our last meeting as presented.*	*D. Dolores*	*Resolved*	
PBM Update	*D. McFerran provided an update regarding the PBM transition*		*D. McFerran*	*Informational*	
Policies and Procedures	*D. Dolores reviewed the annual review process for policies & procedures. They will be emailed to the committee for review and approval.* • *Coverage Determination and Prior Authorization* • *FDR Oversight* • *Medication Quality Assurance* • *Pharmacy and Therapeutics (P&T) Committee* • *Transition Policy* • *MTM Program* • *Direct Member Reimbursement*		*D. Dolores*	*Informational*	
MTM Program 2027	*K. Koerwitz reviewed the MTM program for 2027*		*K. Koerwitz*	*Informational*	
Bridge Program Update	*H. McCaffrey provided an update on the Bridge Program*		*H. McCaffrey*	*Informational*	

II. Drug Formulary Review/Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING	DUE DATE

2027 Prior Authorization Criteria – CMS Review	*The Committee reviewed the 2027 Prior Authorization Criteria CMS review. The Committee approved as presented:*
	• *Calcitonin Gene-Related Peptide Antagonists (CGRP)*
	  ○ *Aimovig*
	  ○ *Emgality*
	  ○ *Nurtec*
	  ○ *Qulipta*
	• *CFTR Modulators*
	  ○ *Kalydeco*
	  ○ *Orkambi*
	  ○ *Trikafta*
	• *Interferon*
	  ○ *Besremi*
	• *Migraine Agents, Acute*
	  ○ *Dihydroergotamine nasal spray*
		The Committee approved the 2027 Prior Authorization Criteria CMS Review. It will be sent to CMS for approval. (See attached for voting detail)	*S. Jackson*
			M. Smikovecus
			M. Prokopets
			J. Crawford
			J. Zubrzycki
			M. McKenna
			H. McCaffrey
			C. Pinketti
			F. Vaisberg
			R. Prager
			S. Joseph
			J. Samuel
			C. Chan
				Resolved	

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING	DUE DATE

	• *Anti-Infective Agent*
	  ○ *Livtencity*
	  ○ *Pyrimethamine*
	• *Antidepressants*
	  ○ *Zurzuvae*
	• *Colony Stimulating Factors*
	  ○ *Filgrastim agents*
	  ○ *Pegfilgrastim agents*
	• *ROCK2 Inhibitors*
	  ○ *Rezurock*
	• *Soluble Guanylate Cyclase Stimulator (sGC)*
	  ○ *Verquvo*
	• *Gastrointestinal Agents*
	  ○ *Vowst*
	• *Intravenous Immune Globulin (IVIG)*
	  ○ *Gammagard*
	  ○ *Gammagard ERC*
	  ○ *Gammaplex*
	  ○ *Gamunex-C*
	  ○ *Octagam*
	  ○ *Privigen*
	• *Antiseizure Agents*
	  ○ *Fintepla*
	• *Aldosterone Receptor Antagonists*
	  ○ *Kerendia*
	• *Liver Disease*
	  ○ *Rezdiffra*
	• *Pulmonary Arterial Hypertension (PAH) Agents*
	  ○ *Adempas*
	  ○ *Ambrisentan*
	  ○ *Bosentan*
	  ○ *Macitentan*
	• *Phosphodiesterase 5 inhibitors (PDE5i)*
	  ○ *Sildenafil*
	  ○ *Tadalafil PAH*
	• *Pulmonary Agents*
	  ○ *Uptravi*
	  ○ *Winrevair*
	  ○ *Pirfenidone*
	  ○ *Nintedanib*
	• *Lipotropic Agents*
	  ○ *Nexletol*				

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING	DUE DATE
	○ *Nexlizet* • *Cardiovascular Agents, Transthyretin Stabilizer* ○ *Vyndamax* • *Monoclonal Antibody, Respiratory* ○ *Dupixent* ○ *Fasenra* ○ *Nucala* ○ *Xolair* • *Endocrine-Metabolic Agent* ○ *Octreotide* ○ *Somavert* • *Antibacterial Agents* ○ *Xifaxan* • *Antiparkinsonian* ○ *Inbrija* • *Testosterone Products* ○ *Topical and Injectable Testosterone* • *Anabolic Agents for Osteoporosis* ○ *Teriparatide* ○ *Tymlos* • *Inflammatory Conditions, Atopic Dermatitis* ○ *Adbry* ○ *Nemluvio* • *VMAT2 Inhibitors* ○ *Austedo* ○ *Ingrezza* ○ *Tetrabenazine* • *Tuberculosis Agents* ○ *Pretomanid* ○ *Sirtuo* • *Bone-Modifying Agent, Monoclonal Antibody* ○ *Denosumab* • *Vasopressin Antagonist* ○ *Tolvaptan (Jynarque)* • *Inflammatory Conditions* ○ *Adalimumab* ○ *Cosentyx* ○ *Enbrel* ○ *Skyrizi* ○ *Ustekinumab* ○ *Zymfentra* ○ *Otezla*				

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING	DUE DATE
	○ *Tocilizumab* • *Anti-Obesity Agents* ○ *Wegovy injection* ○ *Wegovy tablet* • *IgA Nephropathy (IgAN) Agents* ○ *Filspari* ○ *Tarpeyo* • *Amyloid-Targeted mAbs, Alzheimer's* ○ *Leqembi Iqlik* • *Hematopoietic Agents* ○ *Doptelet* ○ *Eltrombopag* • *Growth Hormone* ○ *Omnitrope* • *Wakefulness Promoting Agents* ○ *Armodafinil* ○ *Modafinil* • *Central Nervous System Agents* ○ *Sodium oxybate* ○ *Tasimelteon* • *Chelating Agents* ○ *Deferasirox* • *Polypharmacy, Opioids and Benzodiazepines* ○ *Lorazepam* • *High Risk Medications* ○ *Amitriptyline* ○ *Amoxapine* ○ *Clomipramine* ○ *Desipramine* ○ *Doxepin* ○ *Imipramine* • *Hepatitis C Agents* ○ *Vosevi*				

III. 2027 Formulary Changes

2027 Proposed Formulary Additions ***Category*** *Insulin, short acting*	*The Committee reviewed the 2027 Proposed Formulary Additions. The Committee approved as presented:*				*The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)*	*S. Jackson*	*Resolved*	
	Drug Name	***6T Premium (HMO-SNP)***	***5T Core (HMO)***	***5T Value (PPO, HMO)***				
	Kirsty 100 unit/mL vial	*T3*	*T3*	*T3*				
	Kirsty 100 unit/mL pen	*T3*	*T3*	*T3*				

Anticoagulants	*Xarelto 10 mg tablet*	*T3, QL 30/30 days*	*T3, QL 30/30 days*	*T3, QL 30/30 days*				
	Xarelto 15 mg tablet	*T3, 60/30 days*	*T3, 60/30 days*	*T3, 60/30 days*				
	Xarelto 20 mg tablet	*T3, QL 30/30 days*	*T3, QL 30/30 days*	*T3, QL 30/30 days*				
	Xarelto Starter Pack 15 & 20 mg tablet	*T3, 51/180 days*	*T3, 51/180 days*	*T3, 51/180 days*				
2027 Fall Limited Window Formulary Additions – Protected Class	*The Committee reviewed the 2027 Fall Limited Window Formulary Additions – Protected Class. The Committee approved as presented.*				*The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)*	*S. Jackson*	*Resolved*	
Category	***Drug Name***	***6T Premium (HMO-SNP)***	***5T Core (HMO)***	***5T Value (PPO, HMO)***				
Interferons	*Besremi 500 mcg/0.5mL pen*	*T5, PA, QL 2/28 days*						
Antineoplastics	*Jideytro 100 mg tablet*	*T5, PA, QL 30/30 days*						
	Jideytro 25 mg tablet	*T5, PA, QL 90/30 days*						
	Yulithira 2.5, 5, 7.5, 10 mg tablet	*T3, PA, QL 30/30 days*						
	Zenbexus 0.75, 1 mg capsule	*T5, PA, QL 21/28 days*						
2027 Fall Limited Window Formulary Additions – Non-Protected Class	*The Committee reviewed the 2027 Fall Limited Window Formulary Additions – Non-Protected Class. The Committee approved as presented.*				*The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)*	*S. Jackson*	*Resolved*	
Category	***Drug Name***	***6T Premium (HMO-SNP)***	***5T Core (HMO)***	***5T Value (PPO, HMO)***				
CNS Agents	*Dextromethorphan hbr-quinidine sulfate 20-10 mg cap*	*T5, PA, QL 60/30 days*						
Antidiabetic agents	*Sitagliptin phos-metformin 50-500 mg, 50-1000 mg ER tab*	*T2, QL 60/30 days*						
	Sitagliptin phos-metformin 100-1000 mg ER tab	*T2, QL 30/30 days*						
Inflammatory Conditions	*Skyrizi 55 mg/0.37 mL PFS*	*T5, PA, QL 2.22/365 days*						
Anticoagulants	*Eliquis 0.15 mg sprinkle capsule*	*T3, QL 70/28 days*						
	Eliquis 0.5 mg soluble tablet	*T3, QL 140/28 days*						

	Eliquis (1.5 mg pack) 3 x 0.5 mg soluble tablet	*T3, QL 420/28 days*				
	Eliquis (2 mg pack) 4 x 0.5 mg soluble tablet	*T3, 560/28 days*				
2027 Formulary Removals	*The Committee reviewed the 2027 Formulary Removals. The Committee approved as presented:* • *Boostrix* • *Humulin R U-500 vial* • *Janumet XR 100-1000 mg tablet** • *Janumet XR 50-1000 mg tablet** • *Janumet XR 50-500 mg tablet** • *Kaletra 400-100 mg/5mL solution* • *Norvir 100 mg packet* • *Nuedexta 20-10 mg capsule** • *Selzentry 20 mg/mL solution* **Brand to be removed, generic to be added.*		*The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)*	*S. Jackson*	*Resolved*	

IV. 2026 Review/Updates

2026 Formulary Additions	*The Committee reviewed the 2026 Formulary Additions. The Committee approved as presented.* • *Beqalzi 1, 5, 20, 80 mg tablet - T5, PA* • *Beqalzi Starter Pack 1 & 5 & 20 & 80 mg tablet - T5, PA* • *Bixlenvo 75-50 mg tablet - T5, QL 30/30 days* • *Etcamah 75 mg tablet - T5, PA* • *Rasonque 100, 150 mg tablet - T5, PA, QL 60/30 days*			*The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)*	*S. Jackson*	*Resolved*	
2026 FRF Formulary Additions Protected Class	*The Committee reviewed the 2026 FRF Formulary Additions Protected Class. The Committee approved as presented.*				*The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)*	*S. Jackson*	*Resolved*	
	Drug Name	***6T Premium (HMO-SNP)***	***5T Core (PPO, HMO)***	***5T Value (PPO, HMO)***				
	Besremi 500 mcg/0.5mL pen	*T5, PA, QL 2/28 days*						
	Jideytro 100 mg tablet	*T5, PA, QL 30/30 days*						
	Jideytro 25 mg tablet	*T5, PA, QL 90/30 days*						
	Yulithira 2.5, 5, 7.5, 10 mg tablet	*T3, PA, QL 30/30 days*						
	Zenbexus 0.75, 1 mg capsule	*T5, PA, QL 21/28 days*						
2026 FRF Formulary Additions Non-Protected Class	*The Committee reviewed the 2026 FRF Formulary Additions Non-Protected Class. The Committee approved as presented.*				*The Committee reviewed. It will be sent to CMS for approval. (See*	*S. Jackson*	*Resolved*	
	Drug Name	***6T Premium (HMO-SNP)***	***5T Core (PPO, HMO)***	***5T Value***				

				(PPO, HMO)	*attached for voting detail)*			
	Dextromethorphan hbr-quinidine sulfate 20-10 mg capsule	*T5, PA, QL 60/30 days*						
	Sitagliptin phos-metformin hcl 50-500 mg, 50-1000 mg ER tablet	*T2, QL 60/30 days*						
	Sitagliptin phos-metformin hcl 100-1000 mg ER tablet	*T2, QL 30/30 days*						
	Skyrizi 55 mg/0.37 mL PFS	*T5, PA*						
2026 FRF Formulary Removals	*The Committee reviewed the 2026 FRF Formulary Removals. The Committee approved as presented.* • *Humulin R U-500 vial* • *Nuedexta 20-10 mg capsule** • *Selzentry 20 mg/mL solution* *These drugs will remain on the formulary until the end of the benefit year unless otherwise noted.* **Brand to be removed, generic to be added.*				*The Committee reviewed. It will be sent to CMS for approval. (See attached for voting detail)*	*S. Jackson*	*Resolved*	
V. New Drug Review	*The following new Protected Class Drugs were reviewed and will be added to the formulary per CMS regulations:* • *Tukysa (tucatinib) Tablets* • *Jaypirca (pirtobrutinib) Tablets* • *Lamlique (lamotrigine)Oral Suspension** • *Welireg (belzutifan) Tablets* • *Lyrfigtu (lirafugratinib) Capsules** • *Inluriyo (imlunestrant) Tablet* • *Ibtrozi (taletrectinib) Capsules* • *Omcazio (cabozantinib) Capsules** • *Hyrnuo (sevabertinib) Tablets* • *Etcamah (camizestrant) Tablets** • *Bixlenvo (bictegravir and lenacapavir) Tablets** • *Rasonque (daraxonrasib) Tablets** • *Tevimbra (tislelizumab-jsgr) Injection* • *Tivicay PD (dolutegravir) Tablets for Oral Suspension* • *Zenbexus (iberdomide) Capsules** *The following medications are Formulary with new FDA-approved indications:* • *Yusimry (adalimumab-aqvh) Injection* • *Olumiant (baricitinib) Tablets* • *Winrevair (sotatercept) for Injection* • *Kerendia (finerenone) Tablets*				*Per CMS regulations, "The P&T committee will make a reasonable effort to review a new FDA approved drug product (or new FDA approved indication) within 90 days of its release onto the market and will make a decision on each new FDA approved drug product (or new FDA approved indication) within 180 days of its release onto the market, or a clinical justification will be provided if this timeframe is not met. Formularies must include substantially*	*R. Baniasadi* *M. Tran*	*Resolved*	

	• *Besremi (ropeginterferon alfa-2b-njft) Injection* • *Stelara (ustekinumab) Injection* • *Spikevax (COVID-19 Vaccine, mRNA) Injection* • *Nuvaxovid (COVID-19 Vaccine, Adjuvanted) Injectable Suspension* • *Comirnaty (COVID-19 Vaccine, mRNA) Injection* • *Mounjaro (tirzepatide) Injection* • *mFLUSIVA (influenza vaccine, mRNA) Injection** *The following medications were reviewed and will be kept as Non-formulary. Prior Authorization criteria will be developed as needed:* • *Hovilpri (pritelivir) Tablets** • *Rhapsido (remibrutinib) Tablets* • *Camzyos (mavacamten) Capsules* • *Juvmo (tavapadon) Tablets** • *Emcitate (tiratricol) Tablets for Oral Suspension** • *Onswik (insulin efsitora alfa-gobe) Injection** • *Aqneursa (levacetylleucine) Granules for Oral Suspension* • *Joenja (leniolisib) Tablets* • *Mimrylo (rusfertide) Lyophilized Powder for Injection** • *Lisraya (brepocitinib) Tablets** • *Lerochol (lerodalcibep-liga) Injection* • *Orzeyful (oveporexton) Tablets** *(*Drug also included in the New Drug Review for Medicaid)*	*all drugs in the six protected categories that are FDA approved by the last CMS specified HPMS formulary upload date for the upcoming contract year. New drugs or newly approved uses for drugs within the six classes that come onto the market after the CMS specified formulary upload date will be subject to an expedited P&T committee review. The expedited review process requires P&T committees to make a decision within 90 days, rather than the normal 180-day requirement. At the end of the 90 day period, these drugs must be added to Part D plan formularies." (See attached for voting detail.)*			

VI. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held February 2027.



11/11/2026

Danielle Dolores, Director of Pharmacy Services Date

APPENDIX I: VOTING GRID

	Danielle Dolores, PharmD	George Downs, PharmD	Lawrence Jones, RPh	Tania Kolev, MD	Hannah McCaffrey	Sanjiv Raj	Kaylei Koerwitz	Heather Scheckner	Merleen Harris-Williams, MD	Demian Elder, MD	Edgar Chou, MD	Comments
Minutes Review/Approval	A	A	E	A	A	E	A	A	A	E	A	*October 2026*
2027 Prior Authorization Criteria – CMS Review	A	A	E	A	A	E	A	A	A	E	A	
2027 Proposed Formulary Additions	A	A	E	A	A	E	A	A	A	E	A	
2027 Fall Limited Window Formulary Additions – Protected Class	A	A	E	A	A	E	A	A	A	E	A	
2027 Fall Limited Window Formulary Additions – Non-Protected Class	A	A	E	A	A	E	A	A	A	E	A	
2027 Formulary Removals	A	A	E	A	A	E	A	A	A	E	A	
2026 Formulary Additions	A	A	E	A	A	E	A	A	A	E	A	
2026 FRF Formulary Additions Protected Class	A	A	E	A	A	E	A	A	A	E	A	
2026 FRF Formulary Additions Non-Protected Class	A	A	E	A	A	E	A	A	A	E	A	
2026 FRF Formulary Removals	A	A	E	A	A	E	A	A	A	E	A	
New Drug Review	A	A	E	A	A	E	A	A	A	E	A	

*A = Approved as presented * R = Rejected * E = Excused from meeting * P = Precluded from vote due to conflict of interest